Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERGENT-3: KarXT in schizophrenia
NCT04738123Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Started Apr 2021; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04738123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04738123.